Temasek holds sale of Watsons shares due to valuation differences

People familiar with the matter disclosed that Temasek temporarily shelved the sale of its minority interest in Changshi and its Watsons group. On September 3, Temasek delayed the sale of its minority stake in Changhe and its Watsons group, according to foreign media reports. Temasek suspended the sale process after failing to agree a valuation with potential buyers, people familiar with the matter said. In addition, in addition to the turmoil in Hong Kong's domestic market, uncertainties surrounding brexit have also affected the retailer's business in the UK. In March, Temasek sought about $3 billion by selling about 10% of its Watsons stake, according to people familiar with the matter. Temasek is considering selling just under half of its 25% stake. People familiar with the matter also pointed out that Tencent may join hands with some investment funds to launch a joint acquisition of Watson's shares. At the same time, these shares also attracted Alibaba's interest. According to the query data of real estate new media, Watson is a brand of Changhe which mainly focuses on health care and beauty. Temasek entered into a business strategy alliance with Changhe in March 2014, and purchased 25% equity of Watson group from Changhe, involving 44 billion Hong Kong dollars.
2026-08-31
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Watsons: suspension of personal care products containing plastic particles
-
Uzbekistan Bets $17 Billion on Chemical Industry Upgrade
-
ADNOC Reroutes Naphtha via Oman to Bypass Hormuz Risk
-
US MDI Supply Squeeze Triggers Price Hikes
-
Saint-Gobain Expands Its Construction Chemicals Operations in Indonesia
-
“Anti-Overcapacity” Backfires: China’s Chemical Industry Trapped in a Hell of Its Own Making—and Global Pushback
-
Indorama Corporation Acquires 100% Stake in Anyang Zhongying Fertilizer
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
From “10,000-Ton Bet” to “5,000-Ton Test”: Acore’s Polyetheramine Dilemma—Is This a Symptom of Industry Winter or the Prelude to Strategic Retreat?
-
Carbon Fiber’s Price Surge Signals a New Era of Strategic Value—and Supply Tension
Recommend Reading
-
“Oil Sheikhs” Buy Germany’s Chemical Crown: A €14.7 Billion Green Gamble or a Power Play in the Age of Carbon Neutrality?
-
The Carbon Tollbooth Is Open: EU’s CBAM Ushers in a New Era of Climate-Linked Trade
-
Sherwin-Williams Surpasses $100 Billion in Market Cap: Is This the ‘Apple Moment’ for Paint, or America’s Industrial ‘One Hundred Years of Solitude’?
-
Domo Chemicals’ Triple Collapse: As Chinese Low-Cost Capacity Meets Europe’s Energy Wall, the First Crack Appears in the Continent’s Chemical Empire
-
Clean Food Group Secures UK, EU, and US Approval for Fermentation-Derived Cosmetic Oils
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
In November, Shandong Local Refineries' Gasoline and Diesel Prices Show Divergence
-
This Week's Styrene Market Fluctuates and Declines (6.8-6.12) in China
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
In November, the coke market in China was mainly strong.